Cartesian Therapeutics (RNAC) Operating Expenses (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Operating Expenses data on file, last reported at $26.6 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $26.6 million, up 15.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $149.8 million (up 72.95% YoY), and the FY2025 annual result was $146.2 million, up 76.55% from the prior year.
• Operating Expenses fell to $26.6 million in Q1 2026 per RNAC's latest filing, from $79.6 million in the prior quarter.
• Over five years, Operating Expenses peaked at $79.6 million in Q4 2025 and troughed at $18.0 million in Q3 2024.
• A 5-year average of $27.3 million and a median of $23.2 million in 2022 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses plunged 41.76% in 2024, then surged 206.43% in 2025.
• A 5-year view of Operating Expenses shows it stood at $25.3 million in 2022, then jumped by 76.34% to $44.6 million in 2023, then sank by 41.76% to $26.0 million in 2024, then surged by 206.43% to $79.6 million in 2025, then tumbled by 66.61% to $26.6 million in 2026.
• Business Quant data shows RNAC's Operating Expenses at $26.6 million in Q1 2026, $79.6 million in Q4 2025, and $21.5 million in Q3 2025.